Article
Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis
4 Oct 2022
Abstract excerpt
People with kidney disease are disproportionately affected by atherosclerosis for unclear reasons. Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived mediator of kidney disease, levels of which are strongly associated with cardiovascular outcomes. We assessed suPAR's pathogenic involvement in atherosclerosis using epidemiologic, genetic, and experimental approaches. We found serum suPAR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
